Cargando…

Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study

Cancer treatments have evolved from indiscriminate cytotoxic agents to selective genome- and immune-targeted drugs that have transformed outcomes for some malignancies.(1) Tumor complexity and heterogeneity suggest that the “precision medicine” paradigm of cancer therapy requires treatment to be per...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sicklick, Jason K., Kato, Shumei, Okamura, Ryosuke, Schwaederle, Maria, Hahn, Michael E., Williams, Casey B., De, Pradip, Krie, Amy, Piccioni, David E., Miller, Vincent A., Ross, Jeffrey S., Benson, Adam, Webster, Jennifer, Stephens, Philip J., Lee, J. Jack, Fanta, Paul T., Lippman, Scott M., Leyland-Jones, Brian, Kurzrock, Razelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553618/ https://www.ncbi.nlm.nih.gov/pubmed/31011206 http://dx.doi.org/10.1038/s41591-019-0407-5

Ejemplares similares

Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study
por: Sicklick, Jason K., et al.
Publicado: (2021)

Attrition of Patients on a Precision Oncology Trial: Analysis of the I‐PREDICT Experience
por: Bohan, Sandy S., et al.
Publicado: (2020)

High prevalence of clonal hematopoiesis‐type genomic abnormalities in cell‐free DNA in invasive gliomas after treatment
por: Okamura, Ryosuke, et al.
Publicado: (2021)

Genomic Assessment of Blood-Derived Circulating Tumor DNA in Patients With Colorectal Cancers: Correlation With Tissue Sequencing, Therapeutic Response, and Survival
por: Kato, Shumei, et al.
Publicado: (2019)

Comprehensive genomic landscape and precision therapeutic approach in biliary tract cancers
por: Okamura, Ryosuke, et al.
Publicado: (2020)

ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy
por: Okamura, Ryosuke, et al.
Publicado: (2020)

Cyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristics
por: Kato, Shumei, et al.
Publicado: (2015)

Concordance between cancer gene alterations in tumor and circulating tumor DNA correlates with poor survival in a real‐world precision‐medicine population
por: Rosenberg, Shai, et al.
Publicado: (2023)

Therapeutic Actionability of Circulating Cell-Free DNA Alterations in Carcinoma of Unknown Primary
por: Kato, Shumei, et al.
Publicado: (2021)

Targeting G(1)/S phase cell-cycle genomic alterations and accompanying co-alterations with individualized CDK4/6 inhibitor–based regimens
por: Kato, Shumei, et al.
Publicado: (2021)

SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer
por: Botta, Gregory P., et al.
Publicado: (2021)

Revisiting Epidermal Growth Factor Receptor (EGFR) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies
por: Kato, Shumei, et al.
Publicado: (2019)

Osteosarcoma with cell-cycle and fibroblast growth factor genomic alterations: case report of Molecular Tumor Board combination strategy resulting in long-term exceptional response
por: Persha, Hanna E., et al.
Publicado: (2022)

Case series of outcomes in advanced cancer patients with single pathway alterations receiving N-of-One therapies
por: Gupta, Diviya, et al.
Publicado: (2022)

Personalized matched targeted therapy in advanced pancreatic cancer: a pilot cohort analysis
por: Shaya, Justin, et al.
Publicado: (2023)

Chromatin remodeling (SWI/SNF) complexes, cancer, and response to immunotherapy
por: Krishnamurthy, Nithya, et al.
Publicado: (2022)

Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer
por: Patel, Hitendra, et al.
Publicado: (2019)

The paradox of cancer genes in non-malignant conditions: implications for precision medicine
por: Adashek, Jacob J., et al.
Publicado: (2020)

The Conundrum of Genetic “Drivers” in Benign Conditions
por: Kato, Shumei, et al.
Publicado: (2016)

Pan-cancer molecular tumor board experience with biomarker-driven precision immunotherapy
por: Louie, Bryan H., et al.
Publicado: (2022)

Cyclin alterations in diverse cancers: outcome and co-amplification network
por: Schwaederlé, Maria, et al.
Publicado: (2014)

Precision medicine‐based therapies in advanced colorectal cancer: The University of California San Diego Molecular Tumor Board experience
por: Louie, Bryan H., et al.
Publicado: (2022)

Actionability and precision oncology
por: Schwaederle, Maria, et al.
Publicado: (2015)

Next generation sequencing demonstrates association between tumor suppressor gene aberrations and poor outcome in patients with cancer
por: Schwaederle, Maria, et al.
Publicado: (2015)

Telomerase Reverse Transcriptase Promoter Alterations Across Cancer Types as Detected by Next-Generation Sequencing: A Clinical and Molecular Analysis of 423 Patients
por: Schwaederle, Maria, et al.
Publicado: (2017)

Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications
por: Helsten, Teresa, et al.
Publicado: (2015)

Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology
por: Patel, Sandip P., et al.
Publicado: (2015)

Genomic landscape of salivary gland tumors
por: Kato, Shumei, et al.
Publicado: (2015)

Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients
por: Charo, Lindsey M., et al.
Publicado: (2020)

Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay
por: Schwaederle, Maria, et al.
Publicado: (2016)

Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy
por: Kato, Shumei, et al.
Publicado: (2020)

Liquid biopsy: current technology and clinical applications
por: Nikanjam, Mina, et al.
Publicado: (2022)

Of Mice, Not Men: When the Bench-to-Bedside Bridge Is Broken
por: Nikanjam, Mina, et al.
Publicado: (2022)

An appraisal of drug development timelines in the Era of precision oncology
por: Jardim, Denis Leonardo, et al.
Publicado: (2016)

Fibroblast growth factor family aberrations in cancers: clinical and molecular characteristics
por: Parish, A, et al.
Publicado: (2015)

Utilizing Tumor and Plasma Liquid Biopsy in Treatment Decision Making for an Estrogen Receptor-Positive Advanced Breast Cancer Patient
por: Xu, Bing, et al.
Publicado: (2017)

LAG‐3 transcriptomic expression patterns across malignancies: Implications for precision immunotherapeutics
por: Adashek, Jacob J., et al.
Publicado: (2023)

Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patients
por: Heestand, Gregory M., et al.
Publicado: (2017)

Rare Tumor Clinic: The University of California San Diego Moores Cancer Center Experience with a Precision Therapy Approach
por: Kato, Shumei, et al.
Publicado: (2017)

Concordance between TP53 alterations in blood and tissue: impact of time interval, biopsy site, cancer type and circulating tumor DNA burden
por: Bieg‐Bourne, Cheyennedra C., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8bc5qk5vc3g1lipkc4uh4mqv0k